RxDoctor Payments Data

Osamu Sakai, MD

Neuroradiology · Boston, MANPI 1770550956

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $84,410 of the $84,410 with a category attached, or 100.0%. Merck accounts for 60.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $39,240 and has fallen 97.5% since, to $1,000 in 2025.

$84,410in general payments, 2019–2025

Across 90 payments — averaging $937.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$51K
  • Pfizer$30K
  • Eli Lilly$4K
$234,428in research payments, 2019–2025

Across 67 payments — averaging $3498.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$141K
  • Beigene (suzhou) Co., Ltd.$42K
  • Beigene USA, Inc.$19K
  • Beigene, Ltd.$17K
  • Philips North America LLC$8K
  • E.r. Squibb & Sons, L.L.C.$7K
  • plus $707 from 1 others

What the payments were for

  • Consulting fees$84,410100%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck75$51,230
Pfizer12$29,680
Eli Lilly3$3,500

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,410 in reported general payments places this provider in the 85th percentile of 35 neuroradiology providers in Massachusetts.

See all neuroradiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$114,126
Medicare patients
1,200
Services billed
4,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuroradiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →